Australia

Vaxine

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Vaxine and Medytox partner on Covid-19 vaccine development

Lead Product(s): COVAX-19

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Medytox

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 25, 2020

Details:

The collaboration aims at developing a Covid-19 vaccine called, COVAX-19®, which is currently undergoing late stage animal testing and is based on Vaxine’s proprietary Advax™ adjuvant technology combined with a recombinant SARS-CoV-2 spike protein.

Starpharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Starpharma to Develop COVID-19 Treatment

Lead Product(s): Astodrimer sodium

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2020

Details:

Starpharma’s antiviral dendrimer, SPL7013, has been shown to have significant activity against SARS-CoV-21 (coronavirus), which causes COVID-19.

Noxopharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Noxopharm Investigating Potential COVID-19 Treatment

Lead Product(s): Idronoxil

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

Noxopharm proposes to evaluate idronoxil use in patients at risk of developing acute respiratory distress syndrome (ARDS) and multi-organ failure associated with COVID-19 infection.